CAMBRIDGE, Mass.--(BUSINESS WIRE)--
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the clinical data presented on brigatinib, the Company’s investigational anaplastic lymphoma kinase (ALK) inhibitor, at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC). Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer of ARIAD will host the call. Dr. Clackson will be joined by Karen Reckamp, MD, associate professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Lung Cancer and Thoracic Oncology Program at City of Hope Comprehensive Cancer Center (COHCCC). The call will be held Wednesday, December 7, 4:00 p.m. Central European Time (10:00 a.m. Eastern Time).
The live webcast can be accessed by visiting the investor relations section of the Company’s website at http://investor.ariad.com. The call can be accessed by dialing 844-249-9386 (domestic) or 270-823-1534 (international) five minutes prior to the start time and providing the pass code 20888507. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
View source version on businesswire.com: http://www.businesswire.com/news/home/20161202005681/en/
